SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and ...

Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, ...

Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...

Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with ...

A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...

Myriad Genetics, Inc. engages in the discovery ... The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...

Myriad Medical Supply today announced that the company has upgraded its portfolio of disposable medical products and hired David Nichols, a veteran leader in the healthcare industry, to serve ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...